Compare ADMA Biologics Inc (ADMA) vs TORM plc (TRMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs TORM plc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while TORM plc trades at $28.97 (market cap $2.87B). The key difference: TORM plc is the larger of the two by market cap, and TORM plc pays a 9.87% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TRMD | |
|---|---|---|
Market Cap | $2.13B | $2.87B |
Sector | Health | Technology |
52-Week High | $20.38 | $34.87 |
52-Week Low | $7.60 | $17.33 |
Enterprise Value | $2.20B | $3.76B |
Dividend Yield | — | 9.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
TRMD trades at $27.99, up 1.05% today, with neutral technical signals and strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.21 and P/B of 1.26, supported by robust profitability including 24.41% net margin and 15.62% ROE. Recent earnings showed mixed results with Q4 2025 beat but Q1 2026 miss, while Q2 2026 expectations are set at $3.3 EPS. The company maintains strong cash generation with $498.9M operating cash flow in 2025 and recently declared a $0.70 dividend.
Outlook remains positive with 100% analyst buy ratings and improving 2026 revenue guidance to $1.4B. Key opportunities include undervaluation relative to peers and strong dividend yield near 9%. Risks include earnings volatility from tanker market fluctuations and negative net cash flow trends. The stock presents value for income-focused investors despite cyclical industry exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
